Intensive care medicine

United Imaging Showcases Pioneering Advances and Reinforces U.S. Growth at RSNA 2023

Retrieved on: 
Tuesday, November 21, 2023
RSNA, Yale University, Patient, Huntsman Cancer Institute, MSK, Neurology, Emergency department, Umi, Booth, Biomedical Research, 2D, Diagnosis, Intensive care medicine, Growth, University of California, Davis, Pro, COVID, UVision Air, NCI-designated Cancer Center, Signal-to-noise ratio, Workforce, Heart, Surgery, ATLAS, Software Upgrade Protocol, MRI, Health, AI, Radiology, UC, Christus Health, UMR, FOV, ACS, Radio, University, CT scan, Jupiter, Intelligence, Philosophy, Vision, Brain, Research, Cardiology, ICU, Abdomen, Radiation, Pelvis, FDA, Joint, Workflow, 3D, Medical device, Pharmaceutical industry, Medical imaging, Metaverse, UDR

HOUSTON, Nov. 21, 2023 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, is set to showcase its comprehensive portfolio of innovative technologies at RSNA 2023.

Key Points: 
  • HOUSTON, Nov. 21, 2023 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, is set to showcase its comprehensive portfolio of innovative technologies at RSNA 2023.
  • Highlighting this growth at RSNA 2023, United Imaging will feature the uMR Jupiter 5T (510k pending; not available commercially in the U.S.), a revolutionary whole-body 5T MRI system.
  • In recognition of exceptional scientific contributions, United Imaging takes pride in celebrating Lingzhi (Lance) Hu, Ph.D, a Vice President at United Imaging Healthcare America, who will be honored as a 2023 Distinguished Investigator at RSNA.
  • RSNA attendees are invited to experience the future of medical imaging at Booth #4100, where United Imaging continues to bridge innovation and patient care through state-of-the-art technologies.

Understanding Survival Factors in Critically Ill Patients on Extracorporeal Membrane Oxygenation

Retrieved on: 
Friday, November 17, 2023
Hospice and palliative medicine, Extracorporeal membrane oxygenation, ECMO, Intensive care unit, Prevalence, Chung-Ang University, Ageing, Risk, ICU, Mortality, Patient, Intensive care medicine, Heart, COVID-19, MAP, Critical care nursing, Survival, Death, Survivor, Professor, Intensive word form, Collaboration, Medical device, Nursing, Pharmaceutical industry

SEOUL, Nov. 17, 2023 /PRNewswire/ -- Extracorporeal membrane oxygenation (ECMO), a widely used life support modality, is associated with a high in-hospital mortality rate. Now, researchers from Chung-Ang University, Korea have assessed the prevalence of ECMO-associated deaths and identified the related risk factors. These findings aim to enhance the management of patients requiring ECMO.

Key Points: 
  • SEOUL, Nov. 17, 2023 /PRNewswire/ -- Extracorporeal membrane oxygenation (ECMO), a widely used life support modality, is associated with a high in-hospital mortality rate.
  • Extracorporeal membrane oxygenation (ECMO) is a vital life support procedure that provides cardiac and respiratory support to critically ill patients.
  • Identifying risk factors for in-hospital mortality and developing standardized nursing practice guidelines for ECMO management may improve survival rates.
  • Title of original paper: Factors associated with 30-day in-hospital mortality in critically ill adult patients receiving extracorporeal membrane oxygenation: A retrospective cohort study

EQS-News: Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation

Retrieved on: 
Thursday, December 14, 2023
University College London, Community-acquired pneumonia, Ventilation, Intensive care medicine, Immunoglobulin A, Mortality, Inflammation, Multiple organ dysfunction syndrome, Plasma, Septic shock, COVID-19, CAP, Antibody, Patient, Oxygen, Sepsis, SCAP, Immunoglobulin M, Immunoglobulin G, Immune system, Failure, Pneumonia, Vaccine, Pharmaceutical industry

The article describes new mechanisms by which trimodulin supports the immune system in patients with severe Community-Acquired Pneumonia (sCAP).

Key Points: 
  • The article describes new mechanisms by which trimodulin supports the immune system in patients with severe Community-Acquired Pneumonia (sCAP).
  • One major characteristic of sCAP patients is that their immune system becomes dysregulated, which results in inflammation.
  • The results reported, support the currently ongoing investigation of trimodulin in artificial ventilated patients with sCAP with evidence of significant inflammation (ESsCAPE trial).
  • In addition, trimodulin is currently also in development for the treatment of hospitalized, oxygen-supported patients with non-severe CAP, including COVID-19 (TRICOVID trial).

Allegheny Health Network Advances Virtual Critical Care Service with Launch of New, In-House 'TeleICU' Program

Retrieved on: 
Wednesday, November 8, 2023
Digital, FDA, Physician, Mortality, Allegheny Center (Pittsburgh), Saint Vincent Hospital, AHN, Digital technology, Cleveland, Caregiver, Intensive care unit, Allegheny Health Network, COVID-19, Telehealth, Hospital, Sleep, Intensive care medicine, Self-harm, Jefferson Health, Hospice and palliative medicine, Nursing, Patient, Northside, Canonsburg Hospital, Nursing care plan, ICU, Health insurance, Medical device, MD, Greater Pittsburgh

PITTSBURGH, Nov. 8, 2023 /PRNewswire-PRWeb/ -- Allegheny Health Network (AHN) and Highmark Health announced today the launch of a new virtual intensive care solution which combines innovative telehealth technology and the clinical expertise of AHN intensivists for centralized, 24/7 monitoring and management of critically ill patients at six of the network's hospitals across western Pennsylvania.

Key Points: 
  • This program proved to be a valuable resource for the network and patients throughout the COVID-19 pandemic, supporting response and care planning.
  • "With the launch of TeleICU, we are pleased to transition our virtual ICU service fully in-house, extending the expertise of our own intensivists across the network and further enhancing the quality of care that we provide."
  • The TeleICU command center is located at 4 Allegheny Center (4AC) on Pittsburgh's Northside nearby AHN Allegheny General Hospital.
  • "The collaborative launch of TeleICU with AHN as the pacesetter marks yet another important milestone along our journey to transform health care."

Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (BIO101) in Brazil

Retrieved on: 
Tuesday, November 7, 2023
EAP, Ageing, ANVISA, Notifiable disease, Therapy, Special access program, Euronext Growth, Covid-19 proxalutamide trial in Brazil, Disease, COVID-19, Partnership, Intensive care medicine, Safety, Patient, Death, Pharmaceutical industry

As part of this partnership, Innovative Solutions Pharma will represent Biophytis in front of the Brazilian agency ANVISA to lift the suspension of the Early Access Program (EAP) authorized at the beginning of 2022.

Key Points: 
  • As part of this partnership, Innovative Solutions Pharma will represent Biophytis in front of the Brazilian agency ANVISA to lift the suspension of the Early Access Program (EAP) authorized at the beginning of 2022.
  • The aim is to offer a therapeutic alternative to prevent death of these patients.
  • Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “Making Sarconeos (BIO101) available to Brazilian patients hospitalized in intensive care due to Covid-19 represents a key step towards bringing our treatment to market.
  • Biophytis aims to start this early access program in Brazil in the first quarter of 2024, and to continue expanding our early access program in France and in other countries.”

Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device

Retrieved on: 
Tuesday, October 31, 2023
FDA, HDE, Food, SCD, MD, Acute kidney injury, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AKI, Dialysis, Immune system, SeaStar, Intensive care medicine, CKRT, Letter, Hospice and palliative medicine, Sepsis, End organ damage, Patient, Label, Failure, Pharmaceutical industry

MINNEAPOLIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its strategic partner, SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for its pediatric Selective Cytopheretic Device (SCD-PED).

Key Points: 
  • MINNEAPOLIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its strategic partner, SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for its pediatric Selective Cytopheretic Device (SCD-PED).
  • The Approvable Letter indicates that SeaStar Medical’s Humanitarian Device Exemption (HDE) application substantially meets the requirements for an Approval Order and outlines remaining administrative steps that must be finalized before the HDE can be active for commercialization.
  • For the SCD-PED, these include revisions to product labeling and minor modifications to the post-approval study plan.
  • Nuwellis and SeaStar Medical previously announced an exclusive U.S. license and distribution agreement for Nuwellis to distribute the SCD-PED.

FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients

Retrieved on: 
Monday, October 30, 2023
FDA, Standard of care, Center for Biologics Evaluation and Research, HDE, Humanitarian Device Exemption, Food, SCD, Mortality, MD, Acute kidney injury, Inflammation, AKI, Hepatorenal syndrome, Dialysis, Cardiorenal syndrome, SeaStar, Intensive care medicine, CKRT, Letter, Neutrophil, Hospice and palliative medicine, Monocyte, Sepsis, Patient, Label, Infection, ICU, Pharmaceutical industry, Medical device, Research

As announced in early October 2023, SeaStar Medical expected the FDA to issue this approvable letter within a month of such announcement.

Key Points: 
  • As announced in early October 2023, SeaStar Medical expected the FDA to issue this approvable letter within a month of such announcement.
  • The issuance by the FDA of an Approvable Letter is a standard step in the approval process of a Humanitarian Device Exemption (HDE) application.
  • The Approvable Letter indicates that SeaStar Medical’s HDE application substantially meets the requirements for an Approval Order and outlines remaining administrative steps that must be finalized before the HDE can be active for commercialization.
  • The SCD-PED-01 (weight range ≥15 kg) and PED-02 (weight range ≥10 kg) studies demonstrated 75% and 83% reductions in mortality, respectively.

Global Platform Study Presents Results to Guide Care of Severely Ill Patients With COVID-19 Using Routinely Available Drugs – Simvastatin and Vitamin C

Retrieved on: 
Wednesday, October 25, 2023
Science, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Hospitals, Clinical Trials, WHO, Urinary tract infection, Survival, FRCP, Patient, Vitamin C, Simvastatin, Royal Victoria Hospital, Montreal, Bronchopneumonia, MPH, Global Coalition Against Pneumonia, Oregon Health & Science University, University, Respiratory tract infection, JAMA, Professor, Vitamin, Multimedia, Queen's University Belfast, University of Pittsburgh School of Medicine, Learning, Critical Care Medicine (journal), COVID, Clinical trial, Intensive care unit, Hospital, NEJM, Probability, Pittsburgh, European Society of Clinical Microbiology and Infectious Diseases, Wilfrid Sellars, SUNY Downstate Health Sciences University, Hospice and palliative medicine, Intensive care medicine, Royal Victoria Hospital, UPMC, Consultant, Ohio State University Wexner Medical Center, Pharmaceutical industry, Dietary supplement, MD

Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.

Key Points: 
  • Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.
  • Through harmonizing two clinical trials – REMAP-CAP and LOVIT-COVID – over 2500 patients in 20 countries took part, including both critically ill and non-critically ill patients with COVID-19 in hospital.
  • It was shown that high dose vitamin C did not improve outcomes for patients.
  • Intravenous Vitamin C for Patients Hospitalized with COVID-19: Two Harmonized Randomized Clinical Trials.

Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic Shock

Retrieved on: 
Thursday, October 19, 2023
Annals of Intensive Care, NYSE, Hospice, Intensive care medicine, Septic shock, Hospices Civils de Lyon, Human, Mortality, IL-6, Chromatin, Fungus, Virus, Pelvic floor dysfunction, Nucleosome, SAPS, Immune system, Animal, NETS, Cancer, SOFA, Sepsis, Patient, Death, Pharmaceutical industry, Veterinary medicine, Volition

Professor Monneret and his team used Volition's automated nucleosome quantification assay, Nu.Q® NETs, to measure nucleosome levels in patients with septic shock and to determine whether there is an association with mortality.

Key Points: 
  • Professor Monneret and his team used Volition's automated nucleosome quantification assay, Nu.Q® NETs, to measure nucleosome levels in patients with septic shock and to determine whether there is an association with mortality.
  • Nu.Q® NETs is a simple, low cost and routine blood test which can detect clinically elevated levels of NETs by identifying the unique biomarker H3.1.
  • Professor Guillaume Monneret, Head of Clinical Immunology Laboratory at Hospices Civils de Lyon, said:
    "This was the first study to investigate both nucleosomes and immunological parameters in septic shock.
  • We saw a significant elevation of nucleosomes in septic shock patients.

Global High Acuity Information Solutions Market Reaches $10.51 Billion in 2022, Poised for Robust 7.07% CAGR Growth to Reach $16.10 Billion by 2028

Retrieved on: 
Thursday, October 19, 2023
Internet of things, Operating, Fetus, Haus, AIMS, Information system, EDIS, Prevalence, Masimo, Health, Data management, Growth, GE, Intensive care unit, Oracle Corporation, Critical, Intensive care medicine, Healthcare industry, EDS, USD, AI, Investment, Patient, McKesson Corporation, ICU, Hospital, Medical device, Ridesharing

The global high acuity information solutions market has achieved a significant size of USD 10.51 billion in 2022 and is expected to exhibit robust growth at a compound annual growth rate (CAGR) of 7.07% during the period 2023-2028, ultimately reaching USD 16.10 billion by 2028.

Key Points: 
  • The global high acuity information solutions market has achieved a significant size of USD 10.51 billion in 2022 and is expected to exhibit robust growth at a compound annual growth rate (CAGR) of 7.07% during the period 2023-2028, ultimately reaching USD 16.10 billion by 2028.
  • The global high acuity information solutions market features intense competition with a multitude of major companies.
  • How has the global high acuity information solutions market performed, and what is its future outlook?
  • What are the drivers, restraints, and opportunities in the global high acuity information solutions market?